Article

The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts.

Clinical Neurology Research Group, Peninsula College of Medicine and Dentistry, Plymouth, UK.
Journal of neurology, neurosurgery, and psychiatry (Impact Factor: 4.87). 09/2010; 81(12):1363-8. DOI: 10.1136/jnnp.2009.204008
Source: PubMed

ABSTRACT The Alzheimer's Disease Assessment Scale Cognitive Behavior Section (ADAS-cog), a measure of cognitive performance, has been used widely in Alzheimer's disease trials. Its key role in clinical trials should be supported by evidence that it is both clinically meaningful and scientifically sound. Its conceptual and neuropsychological underpinnings are well-considered, but its performance as an instrument of measurement has received less attention. Objective To examine the traditional psychometric properties of the ADAS-cog in a large sample of people with Alzheimer's disease.
Data from three clinical trials of donepezil (Aricept) in mild-to-moderate Alzheimer's disease (n=1421; MMSE 10-26) were analysed at both the scale and component level. Five psychometric properties were examined using traditional psychometric methods. These methods of examination underpin upcoming Food and Drug Administration recommendations for patient rating scale evaluation.
At the scale-level, criteria tested for data completeness, scaling assumptions (eg, component total correlations: 0.39-0.67), targeting (no floor or ceiling effects), reliability (eg, Cronbach's α: = 0.84; test-retest intraclass correlations: 0.93) and validity (correlation with MMSE: -0.63) were satisfied. At the component level, 7 of 11 ADAS-cog components had substantial ceiling effects (range 40-64%).
Performance was satisfactory at the scale level, but most ADAS-cog components were too easy for many patients in this sample and did not reflect the expected depth and range of cognitive performance. The clinical implication of this finding is that the ADAS-cog's estimate of cognitive ability, and its potential ability to detect differences in cognitive performance under treatment, could be improved. However, because of the limitations of traditional psychometric methods, further evaluations would be desirable using additional rating scale analysis techniques to pinpoint specific improvements.

0 Bookmarks
 · 
222 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: AimThe present study aimed to investigate whether cognitive reserve (CR), referring here to education and premorbid intelligence (IQ), is associated with the risk for progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD).MethodsA total of 51 patients with MCI and 59 patients with AD were prospectively enrolled for assessment with the Mini-Mental State Examination, the Japanese version of the cognitive subscale of the Alzheimer's Disease Assessment Scale, the Japanese version of the Nelson Adult Reading Test (JART), magnetic resonance imaging (MRI) and single-photon emission computed tomography (SPECT), adjusting for sex, age at diagnosis, age at onset and duration of illness.ResultsSPECT findings showed hypoperfusion in the posterior cingulate gyri and precunei, suggesting that the participants were in the early or mild stage of AD or MCI. Voxel-based morphometry MRI showed no statistical differences between the two groups in gray matter loss in the entorhinal and hippocampal areas; however, multiple logistic regression analysis showed a significant difference in premorbid IQ measured with JART.Conclusion Despite the limitations of the cross-sectional design, the findings suggest that premorbid intellectual function might explain the discrepancy in clinical status between MCI and AD patients with a similar magnitude of brain pathology and comorbid medical disorders. Geriatr Gerontol Int 2014; ●●: ●●–●●.
    Geriatrics & Gerontology International 05/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aging of the population has led to the increase of chronic diseases, especially dementia and cardiovascular diseases, and it has become necessary for their relatives to dedicate more time in caregiving.The objective in the first phase of this study is to evaluate the effectiveness of a Primary Health Care procedure to increase the physical activity of people with dementia and their relative caregivers. Also the effect on the cognitive state and cardiovascular risk will be assessed. Design: Clinical, multicentric and randomized trial. A simple random sampling to select 134 patients diagnosed with dementia will be carried out. After contacting their relatives, his/her participation in the trial will be requested. A basal assessment will be made and the participants will be asigned to control or intervention group (1:1). Variables: The main measure will be the assessment of physical activity (podometer and 7-PAR) in patients and caregivers. In patients with dementia: ADAS-cog, functional degree and cardiovascular risk. In caregivers: cardiovascular risk, general health and quality of life. Intervention: For 3 months, participants will receive instructions to do physical activity with an adapted program. This program will be designed and applied by Primary Health Care professionals in patients with dementia and their caregivers. The control group will receive regular care. Analysis: An intention-to-treat analysis will be carried out by comparing the observed differences between basal, 6 and 12 months measures. Change in the mean of daily steps assessed with the podometer and 7-PAR will be the main result. If the main hypothesis is confirmed, it could be useful to improve the cognitive state of patients with dementia, as well as the cardiovascular risk of all of them. The results can be good to improve technical features of the devices that register the physical activity in the patients with dementia, and it could facilitate its commercialization.Trial registration: Clinical Trials.gov Identifier: NCT02044887.
    BMC Neurology 04/2014; 14(1):63. · 2.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is growing interest in the evaluation of preclinical Alzheimer's disease (AD) treatments. As a result, there is a need to identify a cognitive composite that is sensitive to track preclinical AD decline to be used as a primary endpoint in treatment trials. Longitudinal data from initially cognitively normal, 70- to 85-year-old participants in three cohort studies of aging and dementia from the Rush Alzheimer's Disease Center were examined to empirically define a composite cognitive endpoint that is sensitive to detect and track cognitive decline before the onset of cognitive impairment. The mean-to-standard deviation ratios (MSDRs) of change over time were calculated in a search for the optimal combination of cognitive tests/subtests drawn from the neuropsychological battery in cognitively normal participants who subsequently progressed to clinical stages of AD during 2- and 5-year periods, using data from those who remained unimpaired during the same period to correct for aging and practice effects. Combinations that performed well were then evaluated for representation of relevant cognitive domains, robustness across individual years before diagnosis, and occurrence of selected items within top performing combinations. The optimal composite cognitive test score comprised seven cognitive tests/subtests with an MSDR = 0.964. By comparison, the most sensitive individual test score was Logical Memory Delayed Recall with an MSDR = 0.64. We have identified a composite cognitive test score representing multiple cognitive domains that has improved power compared with the most sensitive single test item to track preclinical AD decline and evaluate preclinical AD treatments. We are confirming the power of the composite in independent cohorts and with other analytical approaches, which may result in refinements, have designated it as the primary endpoint in the Alzheimer's Prevention Initiative's preclinical treatment trials for individuals at high imminent risk for developing symptoms due to late-onset AD.
    Alzheimer's & dementia: the journal of the Alzheimer's Association 04/2014; · 14.48 Impact Factor

Full-text (2 Sources)

View
66 Downloads
Available from
May 29, 2014